fingolimod hydrochloride has been researched along with Disease Exacerbation in 130 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.77) | 18.2507 |
| 2000's | 2 (1.54) | 29.6817 |
| 2010's | 101 (77.69) | 24.3611 |
| 2020's | 26 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, S; Hait, NC; Ichikawa, H; Ikarashi, M; Koyama, Y; Ling, Y; Moro, K; Nagahashi, M; Okuda, S; Sakata, J; Sato, N; Shimada, Y; Takabe, K; Takeuchi, S; Toshikawa, C; Tsuchida, J; Wakai, T | 1 |
| Dahlke, F; Häring, DA; Kappos, L; Kropshofer, H; Kuhle, J; Leppert, D; Meinert, R; Patil, A; Tomic, D | 1 |
| Bawand, R; Fathoallahi, N; Ghiasian, M; Moradi, A | 1 |
| Akbari, M; Doerr, N; Kipp, KR; Marhamati, N; Rinschen, MM; Talbot, JJ; Vuong, S; Wang, Y; Weimbs, T; Wessely, O; West, JD | 1 |
| Dababneh, D; Montalban, X; Muccilli, A; Rotstein, D; Saab, G; Shah, P; Solomon, JM; Sormani, MP; Ye, XY | 1 |
| Cristiano, E; Pappolla, A; Patrucco, L; Rojas, JI; Sánchez, F | 1 |
| Chang, X; Dong, Q; Huang, W; Lu, C; Lu, J; Ngew, KY; Quan, C; Tan, H; Wang, L; Wang, M; Wu, M; Wu, X; Xiao, Y; Yu, J; ZhangBao, J; Zhao, C; Zhou, L | 1 |
| Aaen, G; Abrams, A; Benson, L; Casper, TC; Chitnis, T; Gorman, M; Goyal, M; Krupp, L; Liu, T; Lotze, T; Malani Shukla, N; Manlius, C; Mar, S; Ness, J; Rensel, M; Rodriguez, M; Rose, J; Schreiner, T; Tillema, JM; Waltz, M; Waubant, E; Weinstock-Guttmann, B; Wheeler, Y | 1 |
| Comi, G; Falini, A; Filippi, M; Moiola, L; Preziosa, P; Riccitelli, GC; Rocca, MA; Rodegher, M; Signori, A; Storelli, L | 1 |
| Banwell, B; Chitnis, T; Deiva, K; Gärtner, J; Huppke, P; Krupp, L; Merschhemke, M; Pearce, GL; Stites, T; Waubant, E | 1 |
| Amato, MP; Avolio, C; Bonavita, S; Brescia Morra, V; Capobianco, M; Cocco, E; Comi, G; Conte, A; De Luca, G; De Robertis, F; Gasperini, C; Gatto, M; Gazzola, P; Iaffaldano, A; Iaffaldano, P; Lucisano, G; Lus, G; Maimone, D; Mallucci, G; Maniscalco, GT; Manni, A; Marfia, GA; Paolicelli, D; Patti, F; Pesci, I; Pozzilli, C; Rovaris, M; Salemi, G; Salvetti, M; Spitaleri, D; Totaro, R; Trojano, M; Zaffaroni, M | 1 |
| Kimiskidis, VK; Moschou, M; Notas, K; Orologas, A; Papadaki, E | 1 |
| Andabaka, M; Basile, MS; Cavalli, E; Drulovic, J; Fagone, P; Ivanovic, J; Kalfin, R; Mammana, S; Martinovic, V; Mazzon, E; Mesaros, S; Nicoletti, F; Pekmezovic, T; Pennisi, M; Petralia, MC | 1 |
| Costa, J; Guerreiro, R; Miguel, LS; Pinheiro, B | 1 |
| Bergmann, A; Braune, S; Heer, Y; Jules, E; Lionetto, F; Stühler, E; van Hövell, P; Westermann, C | 1 |
| Filippi, M; Moiola, L; Pagani, E; Preziosa, P; Rocca, MA; Rodegher, M; Storelli, L | 1 |
| Arnold, DL; Banwell, B; Bar-Or, A; Brück, W; Chitnis, T; Gärtner, J; Ghezzi, A; Giovannoni, G; Greenberg, BM; Häring, DA; Krupp, L; Merschhemke, M; Pearce, GL; Rostásy, K; Stites, TE; Tardieu, M; Waubant, E; Wolinsky, JS | 1 |
| Asseyer, S; Bäcker-Koduah, P; Berge, T; Boffa, G; Campi, C; Cellerino, M; Harbo, HF; Høgestøl, E; Inglese, M; Ivaldi, F; Kerlero de Rosbo, N; Lapucci, C; Laroni, A; Novi, G; Palmeri, S; Pardini, M; Paul, F; Piana, M; Rotta, G; Sbragia, E; Uccelli, A; Vila, G; Villoslada, P | 1 |
| Álvarez-Cermeño, JC; Ayuso, T; Contreras Martín, Y; Durán, C; Herrera Navarro, N; Martínez-Yelamos, S; Meca-Lallana, J; Meca-Lallana, V; Millán Pascual, J; Pérez Sempere, A; Ricart, J; Romero Sevilla, R | 1 |
| Boffa, G; Bruschi, N; Capello, E; Cellerino, M; Inglese, M; Lapucci, C; Novi, G; Sbragia, E; Uccelli, A | 1 |
| Berger, T; Enzinger, C; Guger, M; Kalcher, S; Kraus, J; Kvas, E; Leutmezer, F | 3 |
| Angarano, G; Bavaro, DF; Bollo, L; Guerra, T; Iaffaldano, P; Monno, L; Paolicelli, D; Saracino, A; Trojano, M | 1 |
| Bhattacharyya, PK; Fox, RJ; Li, H; Lin, J; Lowe, MJ; Sakaie, KE | 1 |
| Alroughani, R; Ampapa, R; Barnett, M; Bergamaschi, R; Boz, C; Butler, E; Butzkueven, H; Cristiano, E; Csepany, T; Diouf, I; Duquette, P; Ferraro, D; Girard, M; Grammond, P; Grand'Maison, F; Granella, F; Gray, O; Havrdova, EK; Hodgkinson, S; Horakova, D; Hughes, S; Hupperts, R; Izquierdo, G; Jokubaitis, V; Kalincik, T; Kermode, A; Lechner-Scott, J; Lugaresi, A; Malpas, C; McCombe, P; Moore, F; Olascoaga, J; Piroska, I; Prat, A; Prevost, J; Pucci, E; Ramo-Tello, C; Rozsa, C; Saladino, ML; Sanchez-Menoyo, JL; Sas, A; Sharmin, S; Shaw, C; Shaygannejad, V; Shuey, N; Simo, M; Singhal, B; Sirbu, CA; Skibina, O; Slee, M; Sola, P; Spelman, T; Spitaleri, D; Taylor, B; Terzi, M; Trojano, M; van der Walt, A; Van Pesch, V; Vucic, S | 1 |
| Chang, D; Chen, W; Cheng, Y; Dai, W; Fan, L; Ge, S; Guo, K; Li, M; Li, Y; Liu, L; Liu, T; Luo, R; Pei, G; Wang, Z; Xu, G; Xu, Y; Yao, Y; Zhang, C; Zhang, N; Zuo, M | 1 |
| Bertolotto, A; Capobianco, M; Malucchi, S | 1 |
| Adlard, N; Brennan, R; Cameron, C; Dahlke, F; Drudge, C; Haltner, A; Samjoo, IA; Spin, P; Worthington, E | 1 |
| Genovese, F; Hijmans, RS; Karsdal, MA; Navis, G; Rasmussen, DG; van den Born, J; van Goor, H; Yazdani, S | 1 |
| de Paula Faria, D; de Vries, EFJ; Dierckx, RAJO; Doorduin, J; Vállez García, D | 1 |
| Alsop, J; Cornelissen, C; Medin, J; Vormfelde, SV; Ziemssen, T | 1 |
| Achiron, A; Alroughani, R; Aref, H; Bijarnia, M; Cooke, K; Harb, M; Inshasi, J; Yuksel, O | 1 |
| Havla, J; Hohlfeld, R; Kümpfel, T; Meinl, I | 1 |
| Brück, W; Ellenberger, D; Gärtner, J; Hummel, H; Huppke, B; Huppke, P; Rostasy, K; Stark, W | 1 |
| Fernández, Ó | 1 |
| Hongell, K; Meier, DP; Ritter, S; Silva, DG; Soilu-Hänninen, M | 1 |
| Calkwood, J; Khan, N; Korn, JR; Lathi, E; Medin, J; Silva, D; Silversteen, J; Weinstock-Guttman, B; Zivadinov, R | 1 |
| Bachmann, V; Baumann, A; Czaplinski, A; Findling, O; Kamm, CP; Lalive, PH; Perriard, G; Pless, ML; Roth, S; Zecca, C | 1 |
| Fukazawa, T; Kinoshita, M; Koda, T; Kumanogoh, A; Miyazaki, Y; Mochizuki, H; Nakatsuji, Y; Namba, A; Niino, M; Okuno, T; Shimizu, M; Sugimoto, T; Takata, K; Yamashita, K | 1 |
| Gaetano, L; Häring, DA; Kappos, L; Mueller-Lenke, N; Radue, EW; Sprenger, T; Thakur, A; Tomic, D | 1 |
| Benkert, P; Derfuss, T; Hänni, P; Kappos, L; Kuhle, J; Lienert, C; Lorscheider, J; Yaldizli, Ö | 1 |
| Fukazawa, T; Kawashima, A; Miyazaki, Y; Niino, M; Sato, K; Yamada, M | 1 |
| Alvarez, E; Bergsland, N; Chitnis, T; Cohan, S; Dwyer, MG; Hunter, SF; Khan, N; Kinkel, P; Korn, JR; Medin, J; Naismith, RT; Silva, D; Weinstock-Guttman, B; Zivadinov, R | 1 |
| Bajrami, A; Calabrese, M; Castellaro, M; Monaco, S; Montemezzi, S; Pitteri, M; Pizzini, F; Romualdi, C | 1 |
| Cascione, M; Cree, BAC; Meng, X; Schofield, L; Tenenbaum, N; Wendt, J | 1 |
| Ahn, SW; Cho, JY; Huh, SY; Hyun, JW; Kim, BJ; Kim, HJ; Kim, SH; Kim, W; Lee, SH; Park, MS | 1 |
| Barrero, F; En Representacion de Los Investigadores Del Estudio Ms Next, ERLIDEMN; Garcia, E; Mallada-Frechin, J; Martinez-Gines, ML; Marzo-Sola, ME; Meca-Lallana, V; Ricart, J | 1 |
| Butzkueven, H; Hall, AJ; Lim, LL; Lo, TC; Pimentel, RS; Silva, DG | 1 |
| De Stefano, N; Giovannoni, G; Haering, DA; Kappos, L; Langdon, D; Piani-Meier, D; Sormani, MP; Tomic, D | 1 |
| Aufenberg, C; Doerck, S; Eienbroeker, C; Haas, J; Kleinschnitz, C; Klotz, L; Lang, M; Lee, DH; Limmroth, V; Linker, RA; Meuth, SG; Pawlitzki, M; Pfeuffer, S; Pul, R; Ruck, T; Schmidt, R; Straeten, FA; Straeten, V; Tackenberg, B; Wiendl, H; Wieshuber, M; Wildemann, B; Windhagen, S | 1 |
| Bajer-Kornek, B; Berger, T; Deisenhammer, F; Walter, E | 1 |
| Alroughani, R; Bergamaschi, R; Brown, JWL; Butzkueven, H; Coles, A; Duquette, P; Ferraro, D; Flechter, S; Girard, M; Grammond, P; Grand'Maison, F; Granella, F; Harding, K; Havrdova, E; Horakova, D; Hupperts, R; Hutchinson, M; Izquierdo, G; Jokubaitis, V; Jones, J; Kalincik, T; Lechner-Scott, J; Lugaresi, A; McCombe, P; McGuigan, C; Pearson, OR; Prat, A; Pucci, E; Rice, C; Robertson, N; Scolding, N; Shaygannejad, V; Slee, M; Sola, P; Terzi, M; Trojano, M; Van Pesch, V; Wilkins, A; Willis, M; Ziemssen, T | 1 |
| Harding, K; Hrastelj, J; Joseph, F; Pickersgill, T; Rimmer, A; Robertson, N; Tallantyre, E; Tomassini, V; Wardle, M; Williams, O; Willis, M | 1 |
| Berardi, A; Harty, G; Siddiqui, MK; Treharne, C; Wong, SL | 1 |
| Adoni, T; Fragoso, YD; Gomes, S; Goncalves, MVM; Parolin, LF; Rosa, G; Ruocco, HH | 1 |
| Avendano, S; Cabre, P; de Roquemaurel, A; Galli, P; Landais, A | 1 |
| Polanco, A; Poveda, JL; Rubio-Rodríguez, D; Rubio-Terrés, C; Torres, C; Trillo, JL | 1 |
| Hirano, S; Kojima, K; Kuwabara, S; Masuda, H; Mori, M; Ohtani, R; Uchida, T; Uzawa, A | 1 |
| Berenguer-Ruiz, L; Gimenez-Martinez, J; Palazón-Bru, A; Sempere, AP | 1 |
| Al Khedr, A; Barbin, L; Berger, E; Bourre, B; Brassat, D; Brochet, B; Cabre, P; Camdessanché, JP; Casey, R; Casez, O; Clavelou, P; De Sèze, J; Debouverie, M; Debroucker, T; Defer, G; Edan, G; Foucher, Y; Gout, O; Guennoc, AM; Heinzlef, O; Labauge, P; Labeyrie, C; Laplaud, DA; Lebrun-Frenay, C; Leray, E; Lubetzki, C; Magy, L; Maubeuge, N; Michel, L; Moreau, T; Nifle, C; Papeix, C; Patry, I; Pelletier, J; Rollot, F; Stankoff, B; Thouvenot, E; Tourbah, A; Vermersch, P; Vukusic, S; Wahab, A; Wiertlewski, S | 1 |
| Akatani, R; Chihara, N; Katanazaka, K; Matsumoto, R; Sekiguchi, K; Ueda, T | 1 |
| Bartosik-Psujek, H; Bielecki, B; Brola, W; Ciach, A; Czajka, A; Dorobek, M; Glabinski, A; Kapica-Topczewska, K; Kochanowski, J; Kulakowska, A; Kurkowska-Jastrzebska, I; Kurowska, K; Maciagowska-Terela, M; Nojszewska, M; Podlecka-Pietowska, A; Rusek, S; Siger, M; Stasiolek, M; Stepien, A; Tutaj, A; Walczak, A; Wicha, W; Wlodek, A; Zajdel, R; Zakrzewska-Pniewska, B | 1 |
| Betensky, RA; Chin, P; Eckert, B; Mandel, M; Mercier, F | 1 |
| Chen, J; Chen, P; Liu, B; Ni, H; Pan, M; Zhang, J; Zhang, M | 1 |
| Brieland, JK; Chen, YJ; Kim, JH; O'Neal, J; O'Neil, SP; Song, SK; Trinkaus, K; Tu, TW; Wang, X | 1 |
| Bergmann, A; Braune, S; Lang, M | 2 |
| Agarwal, S; Deniz, B; Fox, RJ; Havrdova, E; Hutchinson, M; Kurukulasuriya, NC; Sarda, SP; Siddiqui, MK; Taneja, A | 1 |
| Cremer, M; de Vera, A; Francis, G; Izquierdo, G; Kappos, L; Montalban, X; O'Connor, P; Radue, EW; Sfikas, N; von Rosenstiel, P | 1 |
| Thomas, K; Ziemssen, T | 1 |
| Anthony, DC; Leppert, D; Losey, P; Meier, DP; Sibson, NR | 1 |
| Agius, M; Chin, P; Grinspan, A; Hashmonay, R; Meng, X | 1 |
| Agius, MA; Calabresi, PA; Cappiello, L; Goodin, D; Jeffery, D; Kappos, L; Li, B; Lublin, FD; Radue, EW; Rammohan, KW; Reder, AT; Stites, T; Vollmer, T; von Rosenstiel, P | 1 |
| Baldi, E; Caniatti, L; Curti, E; Ferraro, D; Granella, F; Guareschi, A; Immovilli, P; Montanari, E; Montepietra, S; Motti, L; Pesci, I; Senesi, C; Simone, AM; Sola, P; Tola, MR; Vitetta, F | 1 |
| McDonald, EA; Sedal, L; Wilson, IB | 1 |
| Batocchi, AP; Bianco, A; De Fino, C; Fetta, A; Frisullo, G; Marti, A; Mirabella, M; Nociti, V; Patanella, AK; Plantone, D; Rossini, PM | 1 |
| Bergvall, N; Cutter, G; Giovannoni, G; Nixon, R; Sfikas, N; Tomic, D | 1 |
| Bencsik, K; Karácsony, M; Vécsei, L | 1 |
| Thomas, RH; Wakefield, RA | 1 |
| Alroughani, R; Barnett, M; Bergamaschi, R; Boz, C; Butzkueven, H; Csepany, T; Duquette, P; Fernandez-Bolanos, R; Girard, M; Grammond, P; Grand'Maison, F; Havrdova, E; Hodgkinson, S; Horakova, D; Hupperts, R; Izquierdo, G; Jokubaitis, V; Kalincik, T; Lechner-Scott, J; Lugaresi, A; McCombe, P; Oreja-Guevara, C; Pucci, E; Rozsa, C; Rum, G; Sanchez-Menoyo, J; Simo, M; Slee, M; Spelman, T; Spitaleri, D; Terzi, M; Trojano, M; Verheul, F | 1 |
| Chin, P; De Stefano, N; Francis, G; Kappos, L; Radue, EW; Sormani, MP; Sprenger, T | 1 |
| Francis, G; Hohlfeld, R; Kappos, L; O'Connor, P; Polman, C; Radue, EW; Ritter, S; Schlosshauer, R; Selmaj, K; von Rosenstiel, P; Zhang-Auberson, L | 1 |
| Gu, Y; He, Z; Liu, H; Lu, M; Wang, C; Wang, H; Yin, J; Zhang, Z; Zheng, G | 1 |
| Banno, R; Fujita, T; Kohno, T; Matsushima, Y; Mikami, N; Miyawaki, M; Otani, F; Takatsuji, M; Tsuji, T; Tsujikawa, K; Yoshida, Y | 1 |
| Adlard, N; Bergvall, N; Griffiths, MJ; Maruszczak, MJ; Montgomery, SM | 1 |
| Deppe, M; Eveslage, M; Gross, CC; Grützke, B; Kirstein, L; Klotz, L; Meuth, SG; Posevitz-Fejfar, A; Schneider-Hohendorf, T; Schwab, N; Wiendl, H | 1 |
| Bergvall, NK; Derfuss, T; Sfikas, N; Tomic, DL | 1 |
| Bae, DS; Cho, YJ; Choi, CH; Choi, JJ; Kim, BG; Kim, HS; Kim, TJ; Lee, JW; Lee, YY; Ryu, JY; Song, SY; Yoon, G | 1 |
| Cerqua, R; Danni, M; Lattanzi, S; Provinciali, L; Silvestrini, M; Taffi, R | 1 |
| Camu, W; Di Cantogno, EV; Jeffery, DR; Meier, DP; Radue, EW; Ritter, S | 1 |
| Chin, P; Kappos, L; Lublin, F; Radue, EW; Ritter, S; Tomic, D | 1 |
| Dong, B; Huang, J; Huang, Y; Kong, W; Xu, Y; Xue, W; Zhang, J; Zhu, Y | 1 |
| Fay, M; Iyer, R; Livingston, T; Mauskopf, J; Sarda, S | 1 |
| Cree, BAC; Freedman, MS; Häring, DA; Hartung, HP; Kappos, L; Li, B; Liu, FC; Lubetzki, C; Lublin, F; Merschhemke, M; Miller, DH; Montalban, X; Putzki, N; Uitdehaag, BMJ; Weiner, H; Wolinsky, JS | 1 |
| Allegood, J; Chalfant, CE; LaVail, MM; Mandal, NA; Matthes, MT; Porter, H; Qi, H; Stiles, M; Sun, E; Tan, J; Yasumura, D | 1 |
| Fan, L; Yan, H | 1 |
| Axelsson, M; Blennow, K; Khademi, M; Lycke, J; Malmeström, C; Novakova, L; Olsson, T; Piehl, F; Zetterberg, H | 1 |
| Cohen, JA; Smith, AL | 1 |
| Koch-Henriksen, N; Magyari, M; Sellebjerg, F; Soelberg Sørensen, P | 1 |
| Batista, S; Correia, I; Ferreira, R; Macário, MC; Marques, IB; Nunes, C; Sousa, L; Sousa, M | 1 |
| Lazibat, I; Rotim, K; Šamija, RK | 1 |
| Cornelissen, C; Kern, R; Ziemssen, T | 1 |
| Chan, A; Edwards, MR; Fox, RJ; Levison, D; Lewin, JB; Marantz, JL; Xiao, J; Zhang, A | 1 |
| Kadlecová, P; Kodým, R; Počíková, Z; Tichá, V | 1 |
| Lasek-Bal, A; Puz, P | 1 |
| Dolgin, E | 1 |
| Bergsland, N; Bonzani, I; Carl, E; Christoffersen, P; Dwyer, MG; Khan, N; Korn, JR; Medin, J; Price, J; Silva, D; Weinstock-Guttman, B; Zivadinov, R | 1 |
| Dive-Pouletty, C; Freedman, MS; Hass, S; Leist, TP; Miller, AE; Montalban, X; Thangavelu, K | 1 |
| Bargiela, D; Bianchi, MT; Chibnik, LB; De Jager, PL; Healy, BC; Westover, MB; Xia, Z | 1 |
| Antel, J; Blain, M; Borucki, DM; Chao, CC; de Lima, KA; Healy, L; Kenison, JE; Quintana, FJ; Rothhammer, V; Takenaka, MC; Tjon, E; Wilz, A | 1 |
| Dikow, R; Gross, ML; Hug, F; Schaier, M; Sommerer, C; Vorwalder, S; Waldherr, R; Zeier, M | 1 |
| Agoropoulou, C; Burtin, P; Calabresi, P; Hohlfeld, R; Kappos, L; Leyk, M; O'Connor, P; Polman, C; Radue, EW; Selmaj, K; Zhang-Auberson, L | 1 |
| Aradhye, S; Barkhof, F; Capra, R; Cohen, JA; Comi, G; de Vera, A; Gallo, P; Hartung, HP; Izquierdo, G; Jin, J; Kappos, L; Khatri, BO; Montalban, X; Pelletier, J; Stites, T; Tiel-Wilck, K; Wu, S | 1 |
| Carroll, WM | 1 |
| Marriott, JJ; O'Connor, PW | 1 |
| Bonzano, L; De Stefano, N; Roccatagliata, L; Sormani, MP | 1 |
| Weinstock-Guttman, B; Yeh, EA | 1 |
| Al-Izki, S; Baker, D; Giovannoni, G; Jackson, SJ; Pryce, G | 1 |
| Konoeda, F; Shichita, T; Yoshimura, A | 1 |
| Gerdes, LA; Havla, JB; Hohlfeld, R; Kümpfel, T; Meinl, I; Pellkofer, HL | 1 |
| Doxani, C; Hadjigeorgiou, GM; Mprotsis, T; Schmid, CH; Zintzaras, E | 1 |
| Agoropoulou, C; Devonshire, V; Francis, G; Häring, DA; Havrdova, E; Kappos, L; O'Connor, P; Radue, EW; Zhang-Auberson, L | 1 |
| Graham-Rowe, D | 1 |
| Bendall, LJ; Bradstock, KF; Don, AS; Hewson, J; Lock, RB; Papa, RA; Qiao, Q; Wallington-Beddoe, CT | 1 |
| Ayala-Perez, R; Fynch, S; Graham, KL; Kay, TW; Krishnamurthy, B; Santamaria, P; Slattery, RM; Thomas, HE | 1 |
| Amato, MP; Giannini, M; Hakiki, B; Pastò, L; Portaccio, E; Razzolini, L | 1 |
| Chaunu, MP; Daelman, L; Maarouf, A; Maitrot, A; Papeix, C; Tourbah, A | 1 |
| Fan, ST; Ho, JW; Lee, TK; Lo, CM; Man, K; Ng, KT; Poon, RT; Sun, CK; Zhao, Y | 1 |
| Furukawa, Y; Hara, M; Hwang, MW; Iwasaki, A; Matsumori, A; Okada, M; Ono, K; Sasayama, S | 1 |
16 review(s) available for fingolimod hydrochloride and Disease Exacerbation
| Article | Year |
|---|---|
Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis.
Topics: Disease Progression; Fingolimod Hydrochloride; Humans; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2022 |
Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
Topics: Alemtuzumab; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Precision Medicine; Risk Assessment; Risk Factors; Treatment Outcome | 2017 |
Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatmen
Topics: Cladribine; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Tablets; Treatment Outcome | 2019 |
Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod.
Topics: Adult; Brazil; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Retrospective Studies; Substance Withdrawal Syndrome | 2019 |
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Topics: Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Disease Progression; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Randomized Controlled Trials as Topic; Recurrence; Sphingosine; Toluidines | 2014 |
Management of fingolimod in clinical practice.
Topics: Administration, Oral; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Secondary Prevention; Sphingosine | 2013 |
Current management of relapsing-remitting multiple sclerosis.
Topics: Administration, Intravenous; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Disease Progression; Drug Administration Schedule; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Risk Assessment; Sphingosine; Toluidines | 2014 |
[[Natalizumab therapy, 2013].
Topics: Adult; Antibodies, Monoclonal, Humanized; Disease Progression; Fingolimod Hydrochloride; Humans; Immunocompromised Host; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2014 |
Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Disease Progression; Drug Approval; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Sphingosine; Toluidines; United States; United States Food and Drug Administration | 2015 |
INNOVATIVE THERAPIES REDEFINE TREATMENT GOALS IN MULTIPLE SCLEROSIS.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Natalizumab; Patient Care Planning | 2016 |
Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
Topics: Administration, Oral; Adult; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome | 2017 |
Emerging therapies in relapsing-remitting multiple sclerosis.
Topics: Adjuvants, Immunologic; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cladribine; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Treatment Outcome | 2010 |
Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.
Topics: Administration, Oral; Brain; Cladribine; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Predictive Value of Tests; Propylene Glycols; Recurrence; Regression Analysis; Reproducibility of Results; Sphingosine; Time Factors; Treatment Outcome | 2011 |
Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
Topics: Activities of Daily Living; Administration, Oral; Bradycardia; Central Nervous System; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Female; Fingolimod Hydrochloride; Herpesviridae Infections; Humans; Immunosuppressive Agents; Macular Edema; Male; Multiple Sclerosis, Relapsing-Remitting; Neuroimmunomodulation; Neurologic Examination; Propylene Glycols; Receptors, Lysosphingolipid; Recurrence; Sphingosine; Treatment Outcome; Young Adult | 2011 |
[Role of T lymphocytes in ischemic brain injury].
Topics: Animals; Antibodies, Neutralizing; Brain Ischemia; Corynebacterium; Cytokines; Disease Progression; Fingolimod Hydrochloride; Humans; Inflammation Mediators; Interleukin-17; Interleukin-23; Mice; Molecular Targeted Therapy; Propylene Glycols; Sphingosine; T-Lymphocytes; Time Factors | 2010 |
Network analysis of randomized controlled trials in multiple sclerosis.
Topics: Disease Progression; Fingolimod Hydrochloride; Humans; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis; Placebos; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine | 2012 |
25 trial(s) available for fingolimod hydrochloride and Disease Exacerbation
| Article | Year |
|---|---|
Baseline retinal nerve fiber layer thickness as a predictor of multiple sclerosis progression: New insights from the FREEDOMS II study.
Topics: Disease Progression; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nerve Fibers; Retina; Tomography, Optical Coherence | 2023 |
Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIG
Topics: Adolescent; Age Factors; Age of Onset; Child; Disability Evaluation; Disease Progression; Double-Blind Method; Endpoint Determination; Female; Fingolimod Hydrochloride; Humans; Interferon beta-1a; Kaplan-Meier Estimate; Male; Multiple Sclerosis; Risk Reduction Behavior; Sphingosine 1 Phosphate Receptor Modulators; Treatment Outcome | 2020 |
Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
Topics: Adult; Atrophy; Brain; Disease Progression; Female; Fingolimod Hydrochloride; Gray Matter; Humans; Immunologic Factors; Longitudinal Studies; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neuroimaging; Prospective Studies; White Matter | 2020 |
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG
Topics: Adolescent; Brain; Child; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Interferon beta-1a; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Neuroimaging; Sphingosine 1 Phosphate Receptor Modulators | 2020 |
Efficacy and safety outcomes in vitamin D supplement users in the fingolimod phase 3 trials.
Topics: Adult; Dietary Supplements; Disability Evaluation; Disease Progression; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Immunosuppressive Agents; International Cooperation; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Regression Analysis; Time Factors; Vitamin D | 2018 |
Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.
Topics: Aged; Atrophy; Disease Progression; Double-Blind Method; Female; Fingolimod Hydrochloride; Gray Matter; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Organ Size; Thalamus; Treatment Outcome; White Matter | 2018 |
The effect of fingolimod on focal and diffuse grey matter damage in active MS patients.
Topics: Adolescent; Adult; Atrophy; Disease Progression; Female; Fingolimod Hydrochloride; Gray Matter; Humans; Immunosuppressive Agents; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Single-Blind Method; Young Adult | 2018 |
Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.
Topics: Adolescent; Adult; Aged; Aggression; Black or African American; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis; Patient Satisfaction; Young Adult | 2018 |
Uveitis in Patients with Multiple Sclerosis in Clinical Trials of Fingolimod: Incidence, Prevalence, and Impact on Disease Course.
Topics: Adult; Disease Progression; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Multiple Sclerosis; Prevalence; Recurrence; Treatment Outcome; Uveitis | 2019 |
Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
Topics: Administration, Oral; Disability Evaluation; Disease Progression; Double-Blind Method; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Time Factors; Treatment Outcome | 2014 |
Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Propylene Glycols; Secondary Prevention; Sphingosine; Time Factors; Treatment Outcome | 2014 |
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Topics: Adolescent; Adult; Disability Evaluation; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Placebos; Propylene Glycols; Secondary Prevention; Sphingosine; Treatment Outcome; Young Adult | 2014 |
Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Topics: Adult; Antibodies, Monoclonal, Humanized; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Recurrence; Registries; Severity of Illness Index; Sphingosine; Treatment Outcome | 2015 |
Fingolimod effect on brain volume loss independently contributes to its effect on disability.
Topics: Adult; Brain; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting | 2015 |
Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.
Topics: Adolescent; Adult; Brain; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Recurrence; Single-Blind Method; Sphingosine; Treatment Outcome; Young Adult | 2015 |
Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.
Topics: Adult; Disease Progression; Drug Monitoring; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Patient Acuity; Secondary Prevention; Treatment Outcome | 2015 |
The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS.
Topics: Adult; Brain; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting | 2016 |
Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis.
Topics: Adult; Brain; Disease Progression; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome | 2016 |
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Treatment Outcome; Young Adult | 2016 |
The effectiveness of fingolimod in a Portuguese real-world population.
Topics: Adolescent; Adult; Aged; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Portugal; Retreatment; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod.
Topics: Disease Progression; Documentation; Drug Monitoring; Electronic Health Records; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Safety; Treatment Outcome | 2016 |
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Crotonates; Dimethyl Fumarate; Disability Evaluation; Disease Progression; Evidence-Based Medicine; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Numbers Needed To Treat; Recurrence; Severity of Illness Index; Toluidines; Treatment Outcome | 2016 |
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Topics: Administration, Oral; Adolescent; Adult; Arrhythmias, Cardiac; Brain; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Fingolimod Hydrochloride; Herpesviridae Infections; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Liver Function Tests; Macular Edema; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Young Adult | 2010 |
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Topics: Administration, Oral; Adolescent; Adult; Arrhythmias, Cardiac; Brain; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Injections, Intramuscular; Intention to Treat Analysis; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Statistics, Nonparametric; Young Adult | 2010 |
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Topics: Administration, Oral; Adult; Disability Evaluation; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; Male; Multiple Sclerosis, Relapsing-Remitting; Proportional Hazards Models; Propylene Glycols; Secondary Prevention; Sex Factors; Sphingosine | 2012 |
89 other study(ies) available for fingolimod hydrochloride and Disease Exacerbation
| Article | Year |
|---|---|
Plasma Sphingosine-1-Phosphate Levels Are Associated with Progression of Estrogen Receptor-Positive Breast Cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Female; Fingolimod Hydrochloride; Gene Expression; Humans; Lymphatic Metastasis; Lysophospholipids; MCF-7 Cells; Middle Aged; Plasma; Receptors, Estrogen; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors | 2021 |
Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
Topics: Acute Disease; Atrophy; Biomarkers; Disease Progression; Fingolimod Hydrochloride; Humans; Intermediate Filaments; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Randomized Controlled Trials as Topic | 2022 |
Effects of disease-modifying treatments discontinuation in patients with relapsing-remitting multiple sclerosis: A 5 year prospective cohort study.
Topics: Adult; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Male; Medication Adherence; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Rituximab; Young Adult | 2022 |
Restoration of atypical protein kinase C ζ function in autosomal dominant polycystic kidney disease ameliorates disease progression.
Topics: Animals; Disease Models, Animal; Disease Progression; Enzyme Activation; Fingolimod Hydrochloride; Humans; Mice; Polycystic Kidney, Autosomal Dominant; Protein Kinase C; TRPP Cation Channels | 2022 |
Brain volume loss and physical and cognitive impairment in naive multiple sclerosis patients treated with fingolimod: prospective cohort study in Buenos Aires, Argentina.
Topics: Adult; Argentina; Biomarkers; Brain; Cognitive Dysfunction; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies | 2022 |
Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments.
Topics: Adolescent; Adult; Child; Demography; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Recurrence | 2023 |
Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.
Topics: Adult; Brain; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Longitudinal Studies; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Treatment Outcome | 2020 |
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register.
Topics: Adult; Disease Progression; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Interferon beta-1a; Italy; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Registries; Retrospective Studies; Severity of Illness Index | 2019 |
Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis: Α case series.
Topics: Adult; Alemtuzumab; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting | 2020 |
In Silico and In Vivo Analysis of IL37 in Multiple Sclerosis Reveals Its Probable Homeostatic Role on the Clinical Activity, Disability, and Treatment with Fingolimod.
Topics: Adult; Case-Control Studies; CD4-Positive T-Lymphocytes; Computer Simulation; Disease Progression; Diseases in Twins; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Humans; Interleukin-1; Male; Middle Aged; Multiple Sclerosis; Recurrence; Twins, Monozygotic; Up-Regulation | 2019 |
Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
Topics: Adult; Age of Onset; Cladribine; Cost-Benefit Analysis; Disease Progression; Female; Fingolimod Hydrochloride; Health Expenditures; Health Resources; Humans; Immunosuppressive Agents; Male; Markov Chains; Middle Aged; Models, Economic; Multiple Sclerosis, Relapsing-Remitting; Portugal; Quality-Adjusted Life Years | 2020 |
Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis.
Topics: Algorithms; Bayes Theorem; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Models, Theoretical; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Precision Medicine; Prognosis; Recurrence; Treatment Adherence and Compliance | 2020 |
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study.
Topics: Adult; Aged; Cross-Sectional Studies; Disease Progression; Female; Fingolimod Hydrochloride; Flow Cytometry; Germany; Humans; Immunologic Factors; Immunophenotyping; Immunotherapy; Italy; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Norway; Spain; Young Adult | 2020 |
Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies; Spain | 2020 |
Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
Topics: Adult; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Infections; Lymphocyte Count; Lymphocytes; Lymphopenia; Male; Multiple Sclerosis; Recurrence; Retrospective Studies; Risk | 2020 |
Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
Topics: Administration, Oral; Adult; Austria; Crotonates; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Outcome Assessment, Health Care; Registries; Severity of Illness Index; Toluidines | 2020 |
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.
Topics: Adult; COVID-19; Crotonates; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Nitriles; SARS-CoV-2; Seroconversion; Toluidines | 2020 |
Changes in structural and functional connectivity during two years of fingolimod therapy for multiple sclerosis.
Topics: Adult; Brain; Diffusion Tensor Imaging; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Male; Middle Aged; Multiple Sclerosis | 2020 |
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years.
Topics: Adult; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Proportional Hazards Models | 2021 |
Tertiary lymphoid organs are associated with the progression of kidney damage and regulated by interleukin-17A.
Topics: Adult; Animals; Disease Progression; Female; Fingolimod Hydrochloride; Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Humans; Immunosuppressive Agents; Interleukin-17; Kidney; Lupus Nephritis; Male; Mice; Mice, Knockout; Middle Aged; Nephrosis, Lipoid; Renal Insufficiency, Chronic; Tertiary Lymphoid Structures | 2021 |
Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case report.
Topics: Adolescent; Child; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome | 2021 |
Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses.
Topics: Antibodies, Monoclonal, Humanized; Azetidines; Benzyl Compounds; Clinical Trials, Phase III as Topic; Disease Progression; Feasibility Studies; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propensity Score | 2021 |
Urinary collagen degradation products as early markers of progressive renal fibrosis.
Topics: Animals; Biomarkers; Collagen Type I; Collagen Type III; Disease Progression; Doxorubicin; Fibrosis; Fingolimod Hydrochloride; Kidney; Male; Proteinuria; Proteolysis; Rats, Wistar | 2017 |
Effect of Preventive and Curative Fingolimod Treatment Regimens on Microglia Activation and Disease Progression in a Rat Model of Multiple Sclerosis.
Topics: Animals; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Microglia; Multiple Sclerosis; Rats | 2017 |
Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Disease Progression; Female; Fingolimod Hydrochloride; Germany; Glatiramer Acetate; Humans; Interferons; Male; Middle Aged; Multiple Sclerosis; Young Adult | 2017 |
Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.
Topics: Adolescent; Adult; Aged; Cohort Studies; Disabled Persons; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Middle East; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Quality of Life; Recurrence; Young Adult | 2017 |
Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Pregnancy Complications; Recurrence | 2018 |
Therapy of highly active pediatric multiple sclerosis.
Topics: Adolescent; Child; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Natalizumab; Outcome Assessment, Health Care; Recurrence; Retrospective Studies; Severity of Illness Index | 2019 |
Real-life clinical use of natalizumab and fingolimod in Austria.
Topics: Adult; Austria; Cohort Studies; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propensity Score; Recurrence; Registries; Treatment Outcome; Young Adult | 2018 |
Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcom
Topics: Adult; Cohort Studies; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Treatment Outcome; Young Adult | 2018 |
Real-life long-term effectiveness of fingolimod in Swiss patients with relapsing-remitting multiple sclerosis.
Topics: Adult; Aged; Cross-Sectional Studies; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Switzerland; Treatment Outcome; Young Adult | 2018 |
Beneficial effects of fingolimod in MS patients with high serum Sema4A levels.
Topics: Adult; Animals; Antirheumatic Agents; Biomarkers; Disease Progression; Drug Evaluation; Drug Evaluation, Preclinical; Drug Resistance; Drug Substitution; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Humans; Immunoglobulin Fc Fragments; Immunoglobulin G; Interferon-beta; Lymphocyte Count; Male; Mice; Mice, Inbred C57BL; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recombinant Fusion Proteins; Retrospective Studies; Semaphorins; Severity of Illness Index; Specific Pathogen-Free Organisms; Treatment Outcome | 2018 |
Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Registries; Treatment Outcome | 2018 |
Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.
Topics: Adult; Contrast Media; Dimethyl Fumarate; Disease Progression; Drug Substitution; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Withholding Treatment | 2018 |
Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.
Topics: Adult; Brain; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Organ Size; Retrospective Studies | 2018 |
Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome.
Topics: Adolescent; Adult; Crotonates; Demyelinating Diseases; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Nitriles; Oligoclonal Bands; Optic Neuritis; Quinolones; Reproducibility of Results; Republic of Korea; Sensitivity and Specificity; Time Factors; Toluidines; Young Adult | 2019 |
[Efficacy and safety of fingolimod in routine clinical practice in patients with relapsing-remitting multiple sclerosis in Spain: an intermediate analysis of the MS NEXT study].
Topics: Adult; Disease Progression; Drug Resistance; Drug Substitution; Female; Fingolimod Hydrochloride; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Retrospective Studies | 2018 |
Learning ability correlates with brain atrophy and disability progression in RRMS.
Topics: Adult; Aptitude; Atrophy; Brain; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Learning; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic | 2019 |
Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.
Topics: Adult; Alemtuzumab; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunomodulation; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Retrospective Studies; Treatment Outcome | 2019 |
Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
Topics: Alemtuzumab; Cost-Benefit Analysis; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Health Services; Health Status Indicators; Humans; Immunosuppressive Agents; Interferon-beta; Markov Chains; Models, Econometric; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Quality-Adjusted Life Years | 2019 |
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
Topics: Adult; Alemtuzumab; Cohort Studies; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Time-to-Treatment | 2019 |
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.
Topics: Activities of Daily Living; Adolescent; Adult; Alemtuzumab; Cohort Studies; Crotonates; Dimethyl Fumarate; Disease Progression; Early Medical Intervention; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferons; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Retrospective Studies; Toluidines; Treatment Outcome; Young Adult | 2019 |
Real-life use of oral disease-modifying treatments in Austria.
Topics: Administration, Oral; Adult; Austria; Cohort Studies; Crotonates; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propensity Score; Recurrence; Registries; Toluidines | 2019 |
Fingolimod for the treatment of multiple sclerosis in French West Indies, a real-world study in patients from African ancestry.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Recurrence; Retrospective Studies; Treatment Outcome; West Indies | 2019 |
Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
Topics: Adult; Cladribine; Cost-Benefit Analysis; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Markov Chains; Multiple Sclerosis, Relapsing-Remitting; Quality-Adjusted Life Years; Spain | 2020 |
Relapse numbers and earlier intervention by disease modifying drugs are related with progression of less brain atrophy in patients with multiple sclerosis.
Topics: Adolescent; Adult; Aged; Atrophy; Brain; Disease Progression; Early Medical Intervention; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Young Adult | 2019 |
Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Glatiramer Acetate; Humans; Immunologic Factors; Interferon-beta; Multiple Sclerosis; Natalizumab; Pregnancy; Pregnancy Complications; Puerperal Disorders; Recurrence; Reproductive Behavior | 2019 |
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.
Topics: Adult; Crotonates; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Toluidines; Treatment Outcome | 2019 |
[Increased disease activity in a case of multiple sclerosis after switching treatment from fingolimod to natalizumab].
Topics: Adult; Antibodies; Disease Progression; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Injections, Intramuscular; Interferon-beta; Lymphocyte Count; Multiple Sclerosis; Natalizumab; Recurrence | 2019 |
Real-world effectiveness of fingolimod in Polish group of patients with relapsing-remitting multiple sclerosis.
Topics: Adult; Disabled Persons; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Poland; Recurrence | 2019 |
Estimating time to disease progression comparing transition models and survival methods--an analysis of multiple sclerosis data.
Topics: Adolescent; Adult; Clinical Trials, Phase III as Topic; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Longitudinal Studies; Male; Middle Aged; Models, Statistical; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Young Adult | 2013 |
FTY720 prevents progression of renal fibrosis by inhibiting renal microvasculature endothelial dysfunction in a rat model of chronic kidney disease.
Topics: Animals; Collagen Type IV; Disease Models, Animal; Disease Progression; Endothelial Cells; Fibronectins; Fibrosis; Fingolimod Hydrochloride; Gene Expression Regulation; Kidney; Kidney Glomerulus; Male; Microvessels; Nitric Oxide; Nitric Oxide Synthase Type III; Propylene Glycols; Rats; Renal Insufficiency, Chronic; Sphingosine; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2013 |
Diffusion tensor imaging detects treatment effects of FTY720 in experimental autoimmune encephalomyelitis mice.
Topics: Animals; Anisotropy; Diffusion Tensor Imaging; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Mice; Mice, Inbred C57BL; Myelin Basic Protein; Propylene Glycols; Sphingosine; Spine | 2013 |
Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort.
Topics: Adult; Antibodies, Monoclonal, Humanized; Cohort Studies; Disease Progression; Female; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Outpatients; Propylene Glycols; Recurrence; Sphingosine | 2013 |
Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model.
Topics: Animals; Blood-Brain Barrier; Brain; Capillary Permeability; Disease Models, Animal; Disease Progression; Fingolimod Hydrochloride; Immunosuppressive Agents; Lymphocytes; Macrophages; Male; Microglia; Multiple Sclerosis; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine | 2014 |
Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
Topics: Adult; Antibodies, Monoclonal, Humanized; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Recurrence; Sphingosine; Treatment Outcome | 2014 |
Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Cohort Studies; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Recurrence; Treatment Outcome | 2015 |
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
Topics: Administration, Oral; Adult; Crotonates; Dimethyl Fumarate; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Models, Statistical; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Outcome Assessment, Health Care; Patient Acuity; Randomized Controlled Trials as Topic; Recurrence; Toluidines | 2014 |
Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Topics: Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Disease Progression; DNA-Binding Proteins; Extracellular Signal-Regulated MAP Kinases; Fingolimod Hydrochloride; Histone Chaperones; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Matrix Metalloproteinase 9; Mice; Neoplasm Staging; Prognosis; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription Factors; Transplantation, Heterologous | 2015 |
Functional Mechanism(s) of the Inhibition of Disease Progression by Combination Treatment with Fingolimod Plus Pathogenic Antigen in a Glucose-6-phosphate Isomerase Peptide-Induced Arthritis Mouse Model.
Topics: Animals; Antigens; Arthritis, Experimental; Arthritis, Rheumatoid; CD4-Positive T-Lymphocytes; Combined Modality Therapy; Disease Models, Animal; Disease Progression; Fingolimod Hydrochloride; Glucose-6-Phosphate Isomerase; Immune Tolerance; Immunosuppressive Agents; Male; Mice, Inbred DBA; Peptides; T-Lymphocytes, Regulatory | 2015 |
Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
Topics: Cost-Benefit Analysis; Dimethyl Fumarate; Disability Evaluation; Disease Progression; England; Fingolimod Hydrochloride; Health Status; Humans; Immunosuppressive Agents; Markov Chains; Models, Econometric; Multiple Sclerosis, Relapsing-Remitting; Quality-Adjusted Life Years; State Medicine | 2015 |
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).
Topics: Disease Progression; Fingolimod Hydrochloride; Humans; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Risk | 2015 |
Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer.
Topics: Adult; Animals; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Fingolimod Hydrochloride; Formaldehyde; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Immunohistochemistry; Lymphatic Metastasis; Mice; Mice, Inbred BALB C; Middle Aged; Neoplasm Transplantation; Paraffin Embedding; Phosphotransferases (Alcohol Group Acceptor); Prognosis; Thiazoles; Uterine Cervical Neoplasms | 2015 |
Prediction of disability progression in fingolimod-treated patients.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Prognosis | 2015 |
Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis.
Topics: Adult; Cohort Studies; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferons; Male; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome | 2016 |
Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
Topics: Adaptor Proteins, Signal Transducing; Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Adult; Aged; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitotane; Neoplasm Invasiveness; RNA Interference; RNA, Messenger; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2016 |
Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Topics: Cost-Benefit Analysis; Delayed-Action Preparations; Dimethyl Fumarate; Disease Progression; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Markov Chains; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Quality-Adjusted Life Years | 2016 |
Sphingolipid profile alters in retinal dystrophic P23H-1 rats and systemic FTY720 can delay retinal degeneration.
Topics: Animals; Biosynthetic Pathways; Disease Progression; Drug Evaluation, Preclinical; Fingolimod Hydrochloride; Photoreceptor Cells, Vertebrate; Rats, Sprague-Dawley; Retinal Dystrophies; Sphingolipids; Sphingomyelin Phosphodiesterase | 2016 |
FTY720 Attenuates Retinal Inflammation and Protects Blood-Retinal Barrier in Diabetic Rats.
Topics: Administration, Oral; Animals; Blood-Retinal Barrier; Blotting, Western; Diabetes Mellitus, Experimental; Disease Progression; Down-Regulation; Fingolimod Hydrochloride; Immunohistochemistry; Immunosuppressive Agents; Male; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptors, Lysosphingolipid; Retinitis; RNA | 2016 |
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
Topics: Adult; Biomarkers; Chemokine CXCL13; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Fingolimod Hydrochloride; Glial Fibrillary Acidic Protein; Humans; Inflammation; Male; Middle Aged; Multiple Sclerosis; Neurofilament Proteins; Treatment Outcome; Young Adult | 2017 |
Multiple sclerosis: Fingolimod failure in progressive MS INFORMS future trials.
Topics: Clinical Trials, Phase III as Topic; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multicenter Studies as Topic; Multiple Sclerosis, Chronic Progressive; Randomized Controlled Trials as Topic; Treatment Failure | 2016 |
A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Prospective Studies; Recurrence; Treatment Outcome | 2017 |
Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.
Topics: Adult; Czech Republic; Disability Evaluation; Disease Progression; Endpoint Determination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Treatment Outcome; Work | 2017 |
Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.
Topics: Adult; Disease Progression; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2016 |
Therapies: Progressive steps.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, CD20; Azetidines; B-Lymphocytes; Benzamides; Benzyl Compounds; Blood-Brain Barrier; Clinical Trials as Topic; Disease Progression; Dogs; Drug Approval; Fingolimod Hydrochloride; Hope; Humans; Male; Mice; Multiple Sclerosis, Chronic Progressive; Neuroprotective Agents; Piperidines; Precision Medicine; Pyridines; Rituximab; Thiazoles; Ubiquinone; United States; United States Food and Drug Administration | 2016 |
An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice-The MS-MRIUS Study.
Topics: Adult; Brain; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Retrospective Studies | 2017 |
Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis.
Topics: Adult; Clinical Decision-Making; Decision Support Techniques; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Male; Markov Chains; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Randomized Controlled Trials as Topic; Risk; Time Factors; Treatment Outcome | 2017 |
Sphingosine 1-phosphate receptor modulation suppresses pathogenic astrocyte activation and chronic progressive CNS inflammation.
Topics: Animals; Astrocytes; Cell Line, Tumor; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Microglia; Monocytes; Multiple Sclerosis, Chronic Progressive; Primary Cell Culture; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Transcriptome | 2017 |
Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomized rats.
Topics: Administration, Oral; Albuminuria; Animals; Blood Pressure; Body Weight; Chemokine CCL2; Chemokine CCL5; Chemokines; Creatinine; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Fibronectins; Fibrosis; Fingolimod Hydrochloride; Gene Expression Regulation; Immunosuppressive Agents; Inflammation Mediators; Kidney; Kidney Failure, Chronic; Lymphocytes; Macrophages; Male; Nephrectomy; Nephritis; Phenotype; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, CCR1; Receptors, CCR2; Receptors, CCR5; Sphingosine; Time Factors; Transforming Growth Factor beta1 | 2009 |
Oral therapy for multiple sclerosis--sea change or incremental step?
Topics: Administration, Oral; Arrhythmias, Cardiac; Cladribine; Disease Progression; Female; Fingolimod Hydrochloride; Herpesviridae Infections; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Male; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2010 |
Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis.
Topics: Animals; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Male; Mice; Nerve Degeneration; Propylene Glycols; Recovery of Function; Sphingosine | 2011 |
Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.
Topics: Brain; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Humans; Immunologic Factors; Interferon-beta; Magnetic Resonance Imaging; Male; Melanoma; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Recurrence; Sphingosine; Treatment Outcome | 2012 |
Drugs: An injection of hope.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal, Humanized; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Inflammation; Multiple Sclerosis; Natalizumab; Nitriles; Propylene Glycols; Quinolones; Risk Assessment; Sphingosine; Toluidines; United States; United States Food and Drug Administration | 2012 |
Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia.
Topics: Animals; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Fingolimod Hydrochloride; Humans; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Neoplasm Staging; Philadelphia Chromosome; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Propylene Glycols; Protein Phosphatase 2; Sphingosine; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Intra-islet proliferation of cytotoxic T lymphocytes contributes to insulitis progression.
Topics: Animals; Cell Proliferation; Diabetes Mellitus, Type 1; Disease Progression; Fingolimod Hydrochloride; Flow Cytometry; Histocompatibility Antigens Class I; Immunohistochemistry; Immunosuppressive Agents; Islets of Langerhans; Mice; Mice, Inbred NOD; Mice, Transgenic; Propylene Glycols; Receptors, Antigen, T-Cell; Sphingosine; T-Lymphocytes, Cytotoxic | 2012 |
Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases.
Topics: Adult; Disability Evaluation; Disease Progression; Drug Administration Schedule; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Time Factors; Treatment Outcome | 2012 |
Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal.
Topics: Adult; Antibodies, Monoclonal, Humanized; Asthenia; Disease Progression; Drug Administration Schedule; Drug Substitution; Epilepsies, Partial; Epilepsy, Tonic-Clonic; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Severity of Illness Index; Sphingosine; Time Factors; Treatment Outcome | 2012 |
Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Down-Regulation; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Immunosuppressive Agents; Liver Neoplasms; Lymphocytes; Neoplasm Transplantation; Propylene Glycols; Proto-Oncogene Proteins c-akt; Rats; Sphingosine; Up-Regulation | 2007 |
FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation.
Topics: Animals; Coronary Artery Disease; Cyclosporine; Disease Progression; Fingolimod Hydrochloride; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Interferon-gamma; Interleukin-2; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred DBA; Postoperative Complications; Propylene Glycols; Sphingosine; T-Lymphocytes, Cytotoxic | 1999 |